Navigation Links
Red-Grape Compound May Improve Diabetes
Date:10/22/2009

But so far resveratrol works only as an injection into the brain of mice, study finds

THURSDAY, Oct. 22 (HealthDay News) -- New research provides further insight into how a health-boosting compound found in red grapes may help the body fend off type 2 diabetes.

But scientists have only seen the effect in mice who received injections in the brain, and no evidence has emerged that consuming red wine or other products made with grapes will alleviate the blood sugar disease.

The findings do tell scientists about how the compound known as resveratrol works on the brain, said senior study author Roberto Coppari.

If scientists know that the brain is a "major player," then drug companies working on related research "will focus on a drug that will penetrate the brain," said Coppari, an assistant professor of internal medicine at University of Texas Southwestern Medical Center in Dallas.

Scientists have been excited about resveratrol, which is found in red grapes, red wine, pomegranates and some other foods, appears to extend the life spans of mice, even those fed a high-fat diet. Resveratrol appears to mimic the effects of severely restricting food intake, which helps a wide variety of animals live longer, Coppari said.

"You can take the spider, fish, and almost every animal in the planet, and give 70 percent of what the animal would normally eat, and you'll see beneficial effects," he said. "Of course, calorie restriction is very difficult to impose on people. You will feel hungry all the time."

In the new study, Coppari and colleagues looked at the effects of resveratrol on diabetes, not life span. Previous research has suggested that the compound helps the body fight off diabetes.

The researchers injected either resveratrol or a placebo into the brains of diet-induced and diabetic mice and watched to see what happened.

Over five weeks, insulin levels returned to half of n
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. New Compound Shrinks Skin Cancers
2. CriticalPoint(TM) Launches Seven New Virtual Compounder(TM) Training Modules
3. NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting
4. Study shows how to boost value of Alzheimers-fighting compounds
5. Compound Targets, Destroys Cancer Stem Cells in Mice
6. First compound that specifically kills cancer stem cells found
7. New class of compounds discovered for potential Alzheimers disease drug
8. DSM Announces SafeBridge(R) Potent Compound Safety Certification
9. New Compounding Pharmacy Videos Provide Product Information, Teach Safety
10. Novel light-sensitive compounds show promise for cancer therapy
11. Neuromed Announces that Merck & Co., Inc. Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3FDA Launches Orphan Drug Workshop at KGI 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 1Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 2Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 3Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 5Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 6Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 1Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 2Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 3Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 1Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 2